Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies [PDF]
Frontiers in Oncology, 2021 Bruton tyrosine kinase (BTK) is a validated target for treatment of B-cell malignancies, and oral inhibitors of BTK have emerged as a standard of care for these diseases.
Hussein A. Abbas, William G. Wierda
doaj +2 more sources
Efficacy and Mechanism EvaluationBackground Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase ...
Jonathan A Cook +16 more
doaj +2 more sources
Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia [PDF]
eJHaemIntroduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects.
Benjamin Heyman +2 more
doaj +2 more sources
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor [PDF]
Current Oncology, 2021 Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL).
Omar Alkharabsheh +3 more
doaj +2 more sources
Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies [PDF]
Cancer MedicineIntroduction Blastoid variant‐mantle cell lymphoma (BV‐MCL) represents an aggressive subset of patients with no established standard of care treatment approach. Methods We performed a retrospective analysis of the clinical characteristics and outcomes of
Benjamin J. Lee +6 more
doaj +2 more sources
The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact [PDF]
Haematologica, 2022 Jonathan J. Pinney +11 more
doaj +2 more sources
Frontiers in Oncology, 2021 Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis.
Ting-Ting Yang +17 more
doaj +1 more source
Frontiers in Oncology, 2021 Vitreoretinal lymphoma (VRL) is a rare intraocular malignancy, and standard treatment approaches have not been defined yet. Bruton tyrosine kinase inhibitors are found to be effective in the treatment of primary central nervous system diffuse large B ...
Liang Wang, Wenxue Guan, Xiaoyan Peng
doaj +1 more source
Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib
Journal of Neurological Surgery Reports, 2022 Spontaneous spinal subdural hematomas (SSH) are rare occurrences that can occur most commonly secondary to vascular malformations or coagulopathies. Only a small fraction of spontaneous SSHs are caused by acquired coagulation disorders such as leukemia ...
John Lynes +7 more
doaj +3 more sources
Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome
Frontiers in Immunology, 2022 Schnitzler syndrome is a rare adult-onset acquired autoinflammatory disorder typically characterized by chronic urticarial rash and immunoglobulin M (IgM) (rarely IgG) monoclonal gammopathy.
Yuehua Huang +6 more
doaj +1 more source